About

A New Approach to Cancer

Treadwell Therapeutics is a clinical-stage oncology company developing first-in-class and best-in-class small molecules to address unmet needs in patients with cancer. Harnessing unique innovations from our founders, partners, and the world-class scientists at Treadwell, we are advancing a pipeline of novel clinical candidates with pan-cancer potential, and a robust multi-modality preclinical pipeline.

Leadership

Shane Burgess, OD, MBA
Co-Chief Executive Officer
Dr. Shane Burgess brings significant entrepreneurial and management experience in the healthcare industry to his role as Co-CEO of Treadwell. In addition to co-founding several successful international companies, including FYiDoctors, Shane has held senior executive roles in organizations ranging from seed-funded start-ups to leading, global companies and has consistently established and led high performing teams to drive innovative product development, deliver entity-wide strategic and operational effectiveness, and achieve transformative corporate and business development results. Shane holds Bachelor of Science and Doctor of Optometry degrees from Canada’s University of Waterloo, and an MBA from Simon Fraser University.

Michael Tusche, PhD MBA
Co-Chief Executive Officer
Dr. Michael Tusche brings over a decade of experience as a scientist, investor, and entrepreneur to his role of co-CEO of Treadwell Therapeutics. Previously, Michael was the Chief Scientific Officer and Co-Founder of Nirsum Laboratories, Inc., a startup Biotechnology company developing small molecule therapeutics for Neuroscience indications. At Nirsum, Dr. Tusche was the Co-inventor of the company’s foundational Intellectual Property and a Principal Investigator of an NIH/NIDA grant, funding the company’s operations into mid-stage clinical studies. Prior to Nirsum, Michael was the Senior Biotechnology Analyst at Mountain Brook Capital Management, LLC, a Healthcare focused Long/Short equity only Hedge Fund, where his focus was Investments in publicly listed Biopharmaceutical companies. Before Mountain Brook, Dr. Tusche was an Associate at MLV and Co., a boutique investment bank with a focus on capital raising and advisory work for Life Science based companies. Dr. Tusche also led Biologic drug discovery at the Campbell Family Institute in Toronto, Canada, where he managed a multidisciplinary R&D team in the pre-clinical development and validation of novel drug candidates. Michael started his career as a Scientist in drug discovery at Bayer AG in Japan, where he worked on early stage development of small molecule GPCR antagonists for allergic and inflammatory diseases.
Dr. Tusche received his B.Sc. (with Distinction) in Biochemistry from the University of Victoria. He also received a Ph.D. in Immunology from the University of Toronto where he trained in the laboratory of Dr. Tak Mak. Michael received his M.B.A. from the University of Toronto. He is co-author on several peer-reviewed publications, the recipient of numerous scientific and business awards, and named inventor on issued US patents focusing on small molecule and biologic therapeutics.

Mark R. Bray, PhD
Co-Founder and Chief Scientific Officer
Dr. Mark Bray is a co-founder of Treadwell and currently serves as Chief Scientific Officer. Dr. Bray played an integral role in the discovery and development of the company’s current clinical pipeline,  and leads the Canadian site of TIO Bioventures’ research and development entity, TIO Discovery. Mark has more than 20 years of experience in drug discovery, preclinical drug development, and research project management in environments ranging from entrepreneurial start-ups to large biopharmaceutical companies. From 2012 to the present, he has directed all activities of the multi-disciplinary drug discovery and development team at Campbell Family Institute for Breast Cancer Research (CFIBCR), University Health Network at Princess Margaret Cancer Centre, where multiple programs have been advanced from discovery to clinical trials under his leadership. Prior to joining the CFIBCR, Mark was Vice President, Research for Rockville, MD-based EntreMed, Inc (now CASI Pharmaceuticals). Dr. Bray co-founded Miikana Therapeutics in 2002, along with Drs. Tak Mak and Gail Eckhardt, and served as Director of Research of Miikana Therapeutics until the company was acquired by EntreMed in 2006. Mark previously held positions at Amgen, acting as scientific liaison between the Toronto-based Amgen Research Institute (ARI) and Amgen’s California headquarters, initiating and leading early stage discovery programs into therapeutic development. He holds a Bachelor of Science degree in microbiology from the University of Toronto and MSc and PhD degrees in microbiology, protein chemistry and enzymology from the University of Guelph.

Ryan Dietz, JD
VP, Corporate Development
Ryan Dietz currently serves as VP, Corporate Development at Treadwell. He brings more than 20 years of experience to the role, having deep experience in technology evaluation, intellectual property generation, licensing and partnering transactions, and company formation. Prior to joining TIO, Ryan was a licensing executive with Boston Children’s Hospital, where he oversaw the hospital’s two largest research programs across all stages of development. During his industry career, Ryan led technology development and intellectual property generation efforts for various prominent start-up biotechnology and pharmaceutical companies including Moderna, Scholar Rock, Magenta Therapeutics, and Morphic Therapeutic. Each of these companies successfully completed IPOs in 2018 or 2019, including the largest IPO in biotechnology history with Moderna raising $620M at a $7.5B valuation. Ryan also has extensive business development and alliance management experience and is an inventor and developer of multiple consumer products for musicians. He holds a Bachelor of Arts degree in psychology and criminal justice from Indiana University Bloomington, and a JD in intellectual property and licensing from Suffolk University Law School.

Tak Wah Mak, PhD
Co-Founder
Perhaps best known for discovering and first cloning the T cell receptor and identifying the function of the CTLA-4 immune checkpoint protein, Dr. Tak Wah Mak is recognized as one of the world’s leading scientists. As Director of the Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre and co-founder of Treadwell, Tak is continuing his quest to study and find cures for the most complex forms of cancer. He has had a uniquely distinguished career in the life science industry having participated in the development of multiple blockbuster oncology therapeutics while Vice President of Research at Amgen, having decades of experience advising global life science venture funds, including Lombard Odier and Aravis, and having co-founded and led multiple successful biopharmaceutical companies, including Agios Pharmaceuticals and Miikana Therapeutics. Tak is a Fellow of the Royal Society of Canada, a recipient of the Gairdner International Award for Science, an Officer of the Order of Canada, and a laureate of the Canadian Medical Hall of Fame (2009). The author of more than 900 scientific publications, Tak has received many distinguished prizes, including the Sloan Award (1996), the Novartis Prize in Immunology (1998), and the Paul Ehrlich Prize (2004). He currently serves on multiple scientific advisory boards, most notably Stand Up To Cancer.